QDEL vs. NEOG, CLDX, NTLA, MYGN, LNTH, SMMT, HIMS, JANX, INDV, and CERT
Should you be buying QuidelOrtho stock or one of its competitors? The main competitors of QuidelOrtho include Neogen (NEOG), Celldex Therapeutics (CLDX), Intellia Therapeutics (NTLA), Myriad Genetics (MYGN), Lantheus (LNTH), Summit Therapeutics (SMMT), Hims & Hers Health (HIMS), Janux Therapeutics (JANX), Indivior (INDV), and Certara (CERT). These companies are all part of the "medical" sector.
Neogen (NASDAQ:NEOG) and QuidelOrtho (NASDAQ:QDEL) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, community ranking and risk.
Neogen has a net margin of 0.17% compared to Neogen's net margin of -0.34%. Neogen's return on equity of 5.54% beat QuidelOrtho's return on equity.
96.7% of Neogen shares are owned by institutional investors. Comparatively, 99.0% of QuidelOrtho shares are owned by institutional investors. 0.7% of Neogen shares are owned by insiders. Comparatively, 1.0% of QuidelOrtho shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Neogen has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, QuidelOrtho has a beta of 0.11, suggesting that its stock price is 89% less volatile than the S&P 500.
In the previous week, QuidelOrtho had 7 more articles in the media than Neogen. MarketBeat recorded 14 mentions for QuidelOrtho and 7 mentions for Neogen. QuidelOrtho's average media sentiment score of 0.36 beat Neogen's score of 0.07 indicating that Neogen is being referred to more favorably in the media.
QuidelOrtho received 109 more outperform votes than Neogen when rated by MarketBeat users. Likewise, 67.23% of users gave QuidelOrtho an outperform vote while only 57.19% of users gave Neogen an outperform vote.
QuidelOrtho has higher revenue and earnings than Neogen. QuidelOrtho is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks.
Neogen presently has a consensus price target of $22.50, suggesting a potential upside of 82.48%. QuidelOrtho has a consensus price target of $61.60, suggesting a potential upside of 51.91%. Given QuidelOrtho's stronger consensus rating and higher probable upside, equities research analysts clearly believe Neogen is more favorable than QuidelOrtho.
Summary
QuidelOrtho beats Neogen on 10 of the 18 factors compared between the two stocks.
Get QuidelOrtho News Delivered to You Automatically
Sign up to receive the latest news and ratings for QDEL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QDEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
QuidelOrtho Competitors List
Related Companies and Tools
